Treatment of childhood kaposiform hemangioendothelioma with sirolimus

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1396-1398

  Blatt, Julie ^a   Stavas, Joseph ^b   Moats Staats, Billie ^a   Woosley, John ^b   Morrell, Dean S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; New agents; Vascular malformations

Indexed keywords

AMINOCAPROIC ACID; BEVACIZUMAB; DEXAMETHASONE; METHYLPREDNISOLONE; PREDNISONE; PROPRANOLOL; RAPAMYCIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TETRADECYL SULFATE SODIUM; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CHEMOEMBOLIZATION; CHILD; CHILDHOOD CANCER; CORTICOSTEROID THERAPY; DRUG MEGADOSE; EPISTAXIS; FEMALE; HEMANGIOENDOTHELIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCLEROTHERAPY; SEPSIS; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR BIOPSY;

ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HEMANGIOENDOTHELIOMA; HUMANS; INFANT; PLATELET COUNT; SIROLIMUS; SKIN NEOPLASMS;

EID: 78049294338     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22766     Document Type: Article

References (15)

1. Weiss SW, Goldblum JR. Hemangioendothelioma: Vascular tumors of intermediate malignancy. In: Weiss SW, Goldblum JR, editors. Enzinger and Weiss's soft tissue tumors. St. Louis: Mosby; 2001. pp. 891-915.
2. Adams DM. The nonsurgical management of vascular lesions. Facial Plast Surg Clin North Am 2001; 9: 601-608.
3. Hartman KR, Moncur JT, Minniti CP, et al. Mediastinal kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in an infant: Treatment with interferon. J Pediatr Hematol Oncol 2009; 31: 690-692.
4. Belmont L, Zemoura L, Couderc LJ. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol 2008; 3: 557-558.
5. Xu ZQ, Liu Y, Wang YX, et al. Therapeutic effects of Avastin on the murine hemangioendothelioma. Beijing Da Xue Xue Bao 2009; 41: 105-108.
6. Shirazi F, Cohen C, Fried L, et al. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 2007; 5: 233-236.
7. Perry B, Banyard J, McLaughlin ER, et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007; 143: 504-506.
8. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
9. Ballou LM, Lin RZ. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008; 1: 27-36; Epub 2008 May 15.
10. Lyons LL, North PE, Mac-Moune Lai F, et al. Kaposiform hemangioendothelioma: A study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 2004; 28: 559-568.
11. Gordillo G, Fang H, Khanna S, et al. Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm. Antioxid Redox Signal 2009; 11: 47-58.
12. O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 1995; 30: 325-329; discussion 329-330.
13. Stacher E, Gruber-Mösenbacher U, Halbwedl I, et al. The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: New potential therapeutic targets? Lung Cancer 2009; 65: 49-55.
14. Saito M, Gunji Y, Kashii Y, et al. Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: A case report. J Pediatr Hematol Oncol 2009; 31: 194-197.
15. Matthews K, Gossett J, Kappelle PV, et al. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: Intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant 2010; 14: 402-408; Epub 2010 Mar 8.